GlassScriptPhysician profile
Matthew Hilgart
NPI 1821756347
$16,933.04
in general payments reported to CMS, 2019-2025
55 companies · $4,978 in 2025
The $4,978 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $245 · 2022: $3,065 · 2023: $4,249 · 2024: $4,395 · 2025: $4,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,313.26 |
| Education | $309.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,137.33 | 2022-2025 | |
| Axsome Therapeutics, INC. | $1,212.11 | 2022-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $951.24 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Pfizer INC. | $894.15 | 2022-2025 | |
| Novo Nordisk INC | $877.78 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $846.98 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $845.66 | 2022-2025 | Trelegy Ellipta, Benlysta |
| Astrazeneca Pharmaceuticals LP | $770.23 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $626.39 | 2022-2025 | Repatha, Otezla, Prolia |
| Teva Pharmaceuticals USA, INC. | $567.98 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $545.94 | 2021-2025 | Xifaxan |
| Corcept Therapeutics | $513.43 | 2024-2025 | Korlym |
| Astellas Pharma US INC | $487.83 | 2023-2025 | Veozah |
| Harmony Biosciences LLC | $477.46 | 2023-2025 | Wakix |
| Alkermes, INC. | $381.28 | 2022-2025 | Aristada, Lybalvi |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $368.38 | 2022-2025 | Zoryve, Seglentis |
| Indivior INC. | $356.82 | 2023-2025 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $326.96 | 2024-2025 | Caplyta |
| Jazz Pharmaceuticals INC. | $313.21 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.71 | 2022-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $287.72 | 2024 | Voquezna |
| Ucb, INC. | $226.94 | 2024-2025 | Bimzelx |
| Biohaven Pharmaceutical Holding Company LTD. | $216.62 | 2022 | |
| Currax Pharmaceuticals LLC | $213.48 | 2022-2024 | Contrave, Nexlizet, Nexletol |
| Vanda Pharmaceuticals INC. | $204.18 | 2024-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $163.72 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $160.99 | 2023-2025 | Ingrezza |
| Avadel Cns Pharmaceuticals, LLC | $141.37 | 2025 | Lumryz |
| Merck Sharp & Dohme LLC | $141.16 | 2022-2023 | Verquvo |
| Lundbeck LLC | $140.96 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $111.66 | 2022-2024 | Takhzyro |
| Janssen Pharmaceuticals, INC | $96.58 | 2022-2024 | Xarelto |
| Sumitomo Pharma America, INC. | $89.34 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $81.06 | 2024-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $67.19 | 2022-2025 | Recorlev |
| Collegium Pharmaceutical, INC. | $65.20 | 2023 | Belbuca, Xtampza |
| Bayer Healthcare Pharmaceuticals INC. | $62.13 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $61.44 | 2022-2023 | |
| Esperion Therapeutics, INC. | $58.50 | 2022-2023 | Nexletol |
| Paratek Pharmaceuticals, INC. | $58.38 | 2022-2025 | Nuzyra |
| Braeburn INC. | $56.85 | 2023-2024 | Brixadi |
| Lucid Diagnostics INC. | $52.72 | 2023 | |
| Almatica Pharma LLC | $51.28 | 2024-2025 | Loreev Xr, Teriparatide |
| Scilex Pharmaceuticals INC. | $46.07 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $45.22 | 2022-2024 | Quviviq |
| Neurelis, INC. | $40.88 | 2023 | Valtoco |
| Genzyme Corporation | $36.27 | 2024 | |
| Tolmar, INC. | $29.91 | 2023-2024 | |
| Grifols USA, LLC | $23.49 | 2024 | Prolastin-C Liquid |
| Halozyme INC | $20.87 | 2023 | |
| Phadia US INC. | $18.71 | 2025 | Immunocap |
| Si-Bone, INC. | $16.54 | 2024 | |
| Acerus Pharmaceuticals Corporation | $14.83 | 2021 | |
| Tms Neurohealth Centers INC. | $14.49 | 2025 | Tms Neurohealth Centers INC. |
| Biohaven Pharmaceuticals, INC. | $12.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Hilgart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.